Great Lakes Advisors LLC Takes $2.10 Million Position in IDEXX Laboratories, Inc. $IDXX

Great Lakes Advisors LLC purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 3,991 shares of the company’s stock, valued at approximately $2,101,000.

Several other hedge funds also recently made changes to their positions in IDXX. Harbour Investments Inc. increased its position in IDEXX Laboratories by 13.3% during the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock worth $92,000 after buying an additional 16 shares during the period. Pinnacle Associates Ltd. raised its position in IDEXX Laboratories by 1.5% in the 4th quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock valued at $830,000 after purchasing an additional 18 shares during the last quarter. Triad Wealth Partners LLC raised its position in IDEXX Laboratories by 3.1% in the 1st quarter. Triad Wealth Partners LLC now owns 600 shares of the company’s stock valued at $337,000 after purchasing an additional 18 shares during the last quarter. Advisory Services Network LLC boosted its stake in IDEXX Laboratories by 2.5% during the 4th quarter. Advisory Services Network LLC now owns 752 shares of the company’s stock worth $509,000 after purchasing an additional 18 shares during the period. Finally, KCM Investment Advisors LLC grew its position in IDEXX Laboratories by 5.3% during the 4th quarter. KCM Investment Advisors LLC now owns 377 shares of the company’s stock worth $255,000 after purchasing an additional 19 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 2.0%

IDEXX Laboratories stock opened at $556.93 on Friday. The stock’s 50 day moving average price is $560.01 and its 200 day moving average price is $576.88. IDEXX Laboratories, Inc. has a 1-year low of $518.55 and a 1-year high of $769.98. The company has a market cap of $43.88 billion, a PE ratio of 39.17, a price-to-earnings-growth ratio of 2.91 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.IDEXX Laboratories’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the company earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on IDXX. Barclays dropped their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Citigroup upped their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. UBS Group increased their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $747.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.